A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

Summary

This is a Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR inhibitor) Treatment in Patients with Advanced Solid Tumors and Hematological Malignancies .

Timeline

Start

2022-07-08

Primary completion

2024-01-08

Completion

2024-01-08

Outcome

Outcome not reported

Stopped: “Lack of efficacy of study compound”

Drugs

Indications